Combination of gefitinib and olaparib versus gefitinib alone in EGFR mutant non-small-cell lung cancer (NSCLC): A randomized phase 2 study (GOAL, Spanish Lung Cancer Group).

Rosario Garcia Campelo,Oscar Gerardo Arrieta-Rodriguez,Bartomeu Massuti,Delvys Rodriguez Abreu,Ana Laura Ortega Granados,Margarita Majem,D. Vicente,P. Lianes,Joaquim Bosch-Barrera,Amelia Insa,Manuel Domine,Noemi Reguart,M. Guirado,Maria Sala,Sergio Vázquez Estévez,Reyes Bernabe Caro,Ana Drozdowskyj,Ana Verdú,Niki Karachaliou,Rafael Rosell

Combination of gefitinib and olaparib versus gefitinib alone in EGFR mutant non-small-cell lung cancer (NSCLC): A randomized phase 2 study (GOAL, Spanish Lung Cancer Group).

2018

9012Background: Low BRCA1 mRNA levels correlate with longer progression free survival (PFS) in erlotinib treated EGFR mutant NSCLC patients (p), while risk of shortened PFS was associated with inte...

Keywords:

non-small cell lung cancer (NSCLC)
Phases of clinical research
Gefitinib
Olaparib
Mutant
Pathology
Lung cancer
Cancer research
Medicine
Erlotinib
Progression-free survival
Oncology
Internal medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations